195 related articles for article (PubMed ID: 19132793)
1. Rheumatoid atlantoaxial subluxation can be prevented by intensive use of traditional disease modifying antirheumatic drugs.
Kauppi MJ; Neva MH; Laiho K; Kautiainen H; Luukkainen R; Karjalainen A; Hannonen PJ; Leirisalo-Repo M; Korpela M; Ilva K; Möttönen T;
J Rheumatol; 2009 Feb; 36(2):273-8. PubMed ID: 19132793
[TBL] [Abstract][Full Text] [Related]
2. Combination drug therapy retards the development of rheumatoid atlantoaxial subluxations.
Neva MH; Kauppi MJ; Kautiainen H; Luukkainen R; Hannonen P; Leirisalo-Repo M; Nissilä M; Möttönen T;
Arthritis Rheum; 2000 Nov; 43(11):2397-401. PubMed ID: 11083260
[TBL] [Abstract][Full Text] [Related]
3. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study.
Korpela M; Laasonen L; Hannonen P; Kautiainen H; Leirisalo-Repo M; Hakala M; Paimela L; Blåfield H; Puolakka K; Möttönen T;
Arthritis Rheum; 2004 Jul; 50(7):2072-81. PubMed ID: 15248204
[TBL] [Abstract][Full Text] [Related]
4. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T;
Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
[TBL] [Abstract][Full Text] [Related]
5. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis.
Mäkinen H; Kautiainen H; Hannonen P; Möttönen T; Leirisalo-Repo M; Laasonen L; Korpela M; Blåfield H; Hakola M; Sokka T
J Rheumatol; 2007 Feb; 34(2):316-21. PubMed ID: 17183623
[TBL] [Abstract][Full Text] [Related]
6. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.
Möttönen T; Hannonen P; Korpela M; Nissilä M; Kautiainen H; Ilonen J; Laasonen L; Kaipiainen-Seppänen O; Franzen P; Helve T; Koski J; Gripenberg-Gahmberg M; Myllykangas-Luosujärvi R; Leirisalo-Repo M;
Arthritis Rheum; 2002 Apr; 46(4):894-8. PubMed ID: 11953964
[TBL] [Abstract][Full Text] [Related]
7. Serum soluble interleukin-2 receptor predicts early remission in patients with recent-onset rheumatoid arthritis treated with a single disease-modifying antirheumatic drug.
Kuuliala A; Leirisalo-Repo M; Möttönen T; Hannonen P; Nissilä M; Kautiainen H; Korpela M; Julkunen H; Hakola M; Repo H;
Clin Exp Rheumatol; 2005; 23(2):243-6. PubMed ID: 15895898
[TBL] [Abstract][Full Text] [Related]
8. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.
Svensson B; Boonen A; Albertsson K; van der Heijde D; Keller C; Hafström I
Arthritis Rheum; 2005 Nov; 52(11):3360-70. PubMed ID: 16255010
[TBL] [Abstract][Full Text] [Related]
9. Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo Trial.
Karstila KL; Rantalaiho VM; Mustonen JT; Möttönen TT; Hannonen PJ; Leirisalo-Repo M; Kaipiainen-Seppänen OA; Karjalainen AH; Korpela MM;
Clin Exp Rheumatol; 2010; 28(1):73-8. PubMed ID: 20346242
[TBL] [Abstract][Full Text] [Related]
10. Cervical Spine Involvement among Patients with Rheumatoid Arthritis Treated Actively with Treat-to-target Strategy: 10-year Results of the NEO-RACo Study.
Sandström T; Rantalaiho V; Yli-Kerttula T; Kautiainen H; Malmi T; Karjalainen A; Uusitalo T; Julkunen H; Kaipiainen-Seppänen O; Paimela L; Puolakka K; Uutela T; Möttönen T; Hannonen P; Leirisalo-Repo M; Laasonen L; Kauppi M;
J Rheumatol; 2020 Aug; 47(8):1160-1164. PubMed ID: 31732558
[TBL] [Abstract][Full Text] [Related]
11. Early Targeted Combination Treatment With Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Long-Term Outcomes in Rheumatoid Arthritis: Ten-Year Follow-Up Results of a Randomized Clinical Trial.
Rantalaiho V; Sandström T; Koski J; Hannonen P; Möttönen T; Kaipiainen-Seppänen O; Yli-Kerttula T; Kauppi MJ; Uutela T; Malmi T; Julkunen H; Laasonen L; Kautiainen H; Leirisalo-Repo M;
Arthritis Care Res (Hoboken); 2019 Nov; 71(11):1450-1458. PubMed ID: 30295425
[TBL] [Abstract][Full Text] [Related]
12. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
Puolakka K; Kautiainen H; Möttönen T; Hannonen P; Korpela M; Julkunen H; Luukkainen R; Vuori K; Paimela L; Blåfield H; Hakala M; Leirisalo-Repo M
Arthritis Rheum; 2004 Jan; 50(1):55-62. PubMed ID: 14730599
[TBL] [Abstract][Full Text] [Related]
13. A 10 year prospective followup of patients with rheumatoid arthritis 1986-96.
Gordon P; West J; Jones H; Gibson T
J Rheumatol; 2001 Nov; 28(11):2409-15. PubMed ID: 11708411
[TBL] [Abstract][Full Text] [Related]
14. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial.
Wassenberg S; Rau R; Steinfeld P; Zeidler H
Arthritis Rheum; 2005 Nov; 52(11):3371-80. PubMed ID: 16255011
[TBL] [Abstract][Full Text] [Related]
15. Failure in longterm treatment is rare in actively treated patients with rheumatoid arthritis, but may be predicted by high health assessment score at baseline and by residual disease activity at 3 and 6 months: the 5-year followup results of the randomized clinical NEO-RACo trial.
Rantalaiho V; Kautiainen H; Järvenpää S; Korpela M; Malmi T; Hannonen P; Kaipiainen-Seppänen O; Yli-Kerttula T; Möttönen T; Mustila A; Karjalainen A; Paimela L; Uutela T; Leirisalo-Repo M;
J Rheumatol; 2014 Dec; 41(12):2379-85. PubMed ID: 25274892
[TBL] [Abstract][Full Text] [Related]
16. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
Ciubotariu E; Gabay C; Finckh A;
J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
[TBL] [Abstract][Full Text] [Related]
17. Stability of the upper neck during isometric neck exercises in rheumatoid arthritis patients with atlantoaxial disorders.
Hakkinen A; Makinen H; Ylinen J; Hannonen P; Sokka T; Neva M; Kautiainen H; Kauppi M
Scand J Rheumatol; 2008; 37(5):343-7. PubMed ID: 18609259
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of occipitocervical subluxation in rheumatoid arthritis patients, using coronal-view reconstructive computed tomography.
Nagayoshi R; Ijiri K; Takenouchi T; Taketomi E; Sakakima H; Komiya S
Spine (Phila Pa 1976); 2009 Nov; 34(24):E879-81. PubMed ID: 19910756
[TBL] [Abstract][Full Text] [Related]
19. Predictors for the progression of cervical lesion in rheumatoid arthritis under the treatment of biological agents.
Kaito T; Ohshima S; Fujiwara H; Makino T; Yonenobu K
Spine (Phila Pa 1976); 2013 Dec; 38(26):2258-63. PubMed ID: 24150439
[TBL] [Abstract][Full Text] [Related]
20. Early and extensive erosiveness in peripheral joints predicts atlantoaxial subluxations in patients with rheumatoid arthritis.
Neva MH; Isomäki P; Hannonen P; Kauppi M; Krishnan E; Sokka T
Arthritis Rheum; 2003 Jul; 48(7):1808-13. PubMed ID: 12847673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
